Dr Reddys gets USFDA EIR for Duvvada facilities
Hyderabad: Pharma major, Dr Reddy's Labs, today announced that the company has received the Establishment Inspection Report (EIR) from the U.S Food and Drug Administration (USFDA) for its formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, indicating closure of the inspection.
Establishment Inspection Report means the closure of inspection.
"Further to our intimation dated October 29, 2021, on the audit conducted by the USFDA at our formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection," the company stated in a BSE filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.